Last updated: May 30, 2026
Zithromax is the branded form of azithromycin, marketed in multiple oral dosage forms (commonly tablets and suspension) by Pfizer in the US. Supply is split between (1) originator-manufactured product for brand demand, (2) FDA-approved generic manufacturers of azithromycin products, and (3) API and intermediate suppliers that feed formulation plants and contract manufacturers. The most actionable way to identify “suppliers” for Zithromax is to start with FDA-labeled manufacturers listed on approved azithromycin NDAs/ANDAs and then trace API makers used by those formulation sites.
Who manufactures Zithromax azithromycin tablets and suspension for the US market?
Answer: Zithromax is marketed by Pfizer; the labeled drug-product manufacturing sites for Zithromax and interchangeable generics are shown in FDA labeling and Orange Book records for each azithromycin product/strength/form. Supply chains differ by dosage form and strength.
Drug product: typical US supply structure
- Brand (Zithromax): Pfizer label holder, with drug-product manufacturing performed at Pfizer and/or contracted manufacturing sites depending on plant footprint and commercialization history.
- Generics and authorized supply: multiple ANDA applicants supply azithromycin tablets, extended release tablets, and oral suspension using contract manufacturing organizations and vertically integrated formulation plants.
- API supply: azithromycin API and intermediates are sourced globally (commonly from China and India supply chains), then made into drug products by FDA-registered formulation facilities.
What “supplier” means in procurement
Procurement teams usually need one of these, each with different risk profiles:
- Drug-product manufacturer (site that makes finished tablets/suspension)
- Packager/labeler (may differ from the maker)
- API supplier (site and quality system)
- Contract manufacturing organization (CMO) used for one or more steps (blending, granulation, filling, packaging)
What FDA-approved generic azithromycin manufacturers supply products that compete with Zithromax?
Answer: Numerous ANDA manufacturers supply azithromycin generics; the highest-confidence supplier list comes from Orange Book listings and FDA labeling for each dosage form and strength.
Dosage forms to map (because supplier sets vary)
- Immediate-release oral tablets (various strengths)
- Oral suspension (powder for reconstitution)
- Extended-release tablets (where applicable, depending on FDA product portfolio)
How to map suppliers fast (commercially actionable method)
- Pull the FDA Orange Book entries for azithromycin products by dosage form and strength.
- For each relevant entry, capture the listed manufacturer sites for the finished dosage form.
- Cross-check each finished site’s labeling in FDA’s “Drugs@FDA” record to confirm the manufacturing/labeler entity.
- Convert supplier lists into a procurement matrix by:
- dosage form
- strength
- packaging configuration
- lead time history (if available)
- known quality notifications (if available)
Which API suppliers make azithromycin used by drug-product manufacturers?
Answer: Azithromycin API is supplied by multiple global API producers; the “supplier” set depends on which ANDA and which formulation site contracts for API.
Typical API sourcing pattern for azithromycin
- API and intermediates are produced by chemical synthesis plants that supply to one or more formulation manufacturers.
- Formulation manufacturers either:
- buy API from an external registered supplier, or
- integrate API supply through affiliate sourcing.
- The API supplier list that matters for your risk assessment is the one tied to the finished dosage form’s specific FDA-approved manufacturing workflow.
API procurement risk drivers
- Regulatory track record of the API manufacturing site
- Batch documentation availability for cGMP release
- Contingency supply for key intermediates
- Change control under the ANDA’s CMC commitments
How do you identify the exact manufacturing sites behind Zithromax and azithromycin generics?
Answer: Use the FDA’s product labeling and Orange Book to identify the labeled drug-product manufacturer and labeler; then connect to the API supply chain through those finished-goods sites’ approved CMC sections.
What to record for each supplier (procurement-ready fields)
- Finished dosage form (tablet/suspension/extended release)
- Strength(s)
- Applicant/holder (for ANDAs, applicant names)
- Labeled manufacturer/packager site
- NDA/ANDA number (or at least Orange Book record ID)
- Formulation technology notes if stated (often limited publicly)
- Any available manufacturing site changes across time
What patent estate and exclusivity does Zithromax have, and how does it affect supplier access?
Answer: Zithromax’s branded protection is time-limited; once patents and regulatory exclusivities expire, the market opens to multiple generic suppliers. Supplier concentration therefore usually shifts from branded to generic once exclusivity ends.
Exclusivity and patent effects on sourcing
- During any remaining branded protection period, sourcing options for generic-like supply are constrained to:
- contract manufacturing for Pfizer under brand,
- authorized generics (if any), or
- non-interchangeable products.
- After expiration, procurement has broader supplier options, but formulation and API supply chain capacity becomes the gating factor.
Which companies typically supply azithromycin suspension and tablet generics that can replace Zithromax?
Answer: The azithromycin generic market is served by multiple multinational and Indian/Chinese generic manufacturers; the exact “who supplies” depends on dosage form and strength and is determined by the labeled manufacturing sites on each approved ANDA.
Why your supplier list can’t be one-size-fits-all
- Some suppliers focus on tablets
- Others focus on suspension
- Some have only specific strengths or package configurations
- Different ANDA manufacturing sites may source API from different chemical suppliers
What generic entry risks exist for Zithromax competitors, and how do they affect supply stability?
Answer: Generic entry risks are driven by FDA compliance and CMC reproducibility rather than patent alone once protection has expired. Supply stability is tied to formulation scale capability, quality outcomes, and ability to sustain API supply.
Risk categories that impact sourcing decisions
- CMC changes (plant/site transfer, process changes)
- API supply disruptions (intermediate availability)
- Sterility of production steps (less relevant for non-sterile oral products but microbiological controls still matter)
- Recall history and FDA inspections affecting batch disposition speed
What is the Orange Book status of Zithromax azithromycin, and which products are substitutable?
Answer: Orange Book records establish whether specific azithromycin products are listed with patents and whether they are subject to market exclusivity. Substitutability in practice is driven by FDA-approved labeling, therapeutic equivalence, and the approved dosage form.
Procurement impact
- If multiple ANDA products list “A” rating (therapeutic equivalence) for the same dosage form/strength, switching suppliers can be operationally feasible.
- If a product is not therapeutically equivalent or has different release characteristics, substitutions are less interchangeable.
Which geographic supply chains dominate azithromycin API and finished dosage manufacturing?
Answer: Azithromycin API supply chains are heavily international; finished dosage manufacturing is distributed across the US, Europe, and major generic-manufacturing hubs, with some reliance on overseas API inputs.
Geographic pattern used by procurement teams
- API: typically China/India-dominant upstream
- Finished dose: a mix of US-based formulation and global ANDA manufacturing sites supplying US markets
Competitive landscape: how supplier options differ between azithromycin tablets vs suspension
Answer: Supplier availability usually differs by formulation complexity. Suspension manufacturing has different constraints than tablets, including filling, reconstitution performance, and packaging stability.
Supplier selection implications
- If you need suspension, verify:
- bottling and filling capability
- shelf-life and stability data
- reconstitution instructions adherence
- If you need tablets, verify:
- compression and coating line capacity
- dissolution profile control
- blister vs bottle packaging capability
Key Takeaways
- “Suppliers for Zithromax” are best defined through FDA-labeled drug-product manufacturers for Zithromax and through ANDA manufacturers for azithromycin generics by dosage form and strength.
- API sourcing is upstream and tied to the specific formulation sites’ approved CMC, so supplier lists for finished goods and API rarely align 1:1.
- Post-exclusivity, supplier breadth increases quickly, but procurement risk shifts to CMC control, API intermediate continuity, and manufacturing site compliance outcomes.
- The highest-confidence supplier mapping comes from Orange Book and FDA labeling tied to each dosage form/strength, not from general brand attribution alone.
FAQs
- How can I find the FDA-labeled manufacturer for a specific strength of azithromycin suspension?
- Which azithromycin generic ANDAs are therapeutically equivalent to Zithromax for oral tablets?
- How do I trace the API supplier behind a specific azithromycin drug-product manufacturer?
- What CMC changes most often disrupt azithromycin generic supply continuity?
- How do packaging format differences (bottle vs blister, suspension bottle size) affect azithromycin supplier availability?
References
- U.S. Food and Drug Administration. Drugs@FDA. Orange Book and product labeling for azithromycin and Zithromax. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Azithromycin entries. https://www.accessdata.fda.gov/scripts/cder/ob/
